Literature DB >> 32958715

Imipenem plus Fosfomycin as Salvage Therapy for Vertebral Osteomyelitis.

Itaru Nakamura1, Tetsuo Yamaguchi2, Kotaro Aoki3, Yuri Miura1, Satoko Sato1, Hiroaki Fujita1, Hidehiro Watanabe1.   

Abstract

We applied combination antibiotic therapy to treat vertebral osteomyelitis and a psoas abscess caused by glycopeptide-intermediate (MIC, 2 μg/ml) and daptomycin-nonsusceptible (>2 μg/ml) methicillin-resistant Staphylococcus aureus The Etest synergy test showed the largest synergistic effects for imipenem/cilastatin and fosfomycin. Whole-gene sequencing showed amino acid changes in SA0802, SA1193 (mprF), and SA1531 (ald). Four weeks of combination treatment using imipenem/cilastatin (1.5 g per day) and fosfomycin (4.0 g per day) resulted in clinical improvement.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Etest synergy test; antibiotic combination; fosfomycin; imipenem; whole genome analysis

Year:  2020        PMID： 32958715      PMCID： PMC7927830          DOI： 10.1128/AAC.01746-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin.

Authors:  O Gasch; M Camoez; M A Domínguez; B Padilla; V Pintado; B Almirante; C Martín; F López-Medrano; E Ruiz de Gopegui; J R Blanco; G García-Pardo; E Calbo; M Montero; A Granados; A Jover; C Dueñas; M Pujol
Journal:  J Antimicrob Chemother       Date:  2013-10-09       Impact factor: 5.790

2.  Combination Therapy against Polymicrobial Infection, Including by NDM-1-Producing Enterobacteriaceae Resistant to Colistin.

Authors:  Itaru Nakamura; Natsuki Sakamoto; Yukiko Ida; Ryutaro Imai; Kotaro Aoki; Rina Ando; Tetsuo Yamaguchi; Hajime Matsumura; Tetsuya Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

3.  Evolution and single-nucleotide polymorphisms in methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to vancomycin and daptomycin, based on determination of the complete genome.

Authors:  Tetsuo Yamaguchi; Shingo Suzuki; Sakiko Okamura; Yuri Miura; Ayaka Tsukimori; Itaru Nakamura; Norihiko Ito; Anri Masuya; Takashi Shiina; Tetsuya Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

4.  Left ventricular assist device-associated endocarditis involving multiple clones of Staphylococcus aureus with distinct antimicrobial susceptibility patterns.

Authors:  Sohei Harada; Kotaro Aoki; Koh Okamoto; Osamu Kinoshita; Kan Nawata; Yoshikazu Ishii; Kazuhiro Tateda; Masakazu Sasaki; Tomoo Saga; Yohei Doi; Hiroshi Yotsuyanagi; Kyoji Moriya; Minoru Ono
Journal:  Int J Infect Dis       Date:  2019-05-07       Impact factor: 3.623

5.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

6.  Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database.

Authors:  José M Miro; Ignasi Anguera; Christopher H Cabell; Anita Y Chen; Judith A Stafford; G Ralph Corey; Lars Olaison; Susannah Eykyn; Bruno Hoen; Elias Abrutyn; Didier Raoult; Arnold Bayer; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2005-07-06       Impact factor: 9.079

7.  In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  Stijn I Blot; Koenraad H Vandewoude; Eric A Hoste; Francis A Colardyn
Journal:  Arch Intern Med       Date:  2002-10-28

9.  Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.

Authors:  Nagendra N Mishra; Soo-Jin Yang; Liang Chen; Claudette Muller; Azzam Saleh-Mghir; Sebastian Kuhn; Andreas Peschel; Michael R Yeaman; Cynthia C Nast; Barry N Kreiswirth; Anne-Claude Crémieux; Arnold S Bayer
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin.

Authors:  Ayaka Tsukimori; Itaru Nakamura; Sakiko Okamura; Akihiro Sato; Shinji Fukushima; Yasutaka Mizuno; Tetsuo Yamaguchi; Tetsuya Matsumoto
Journal:  BMC Infect Dis       Date:  2014-08-23       Impact factor: 3.090
  10 in total
  1 in total

1.  Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy.

Authors:  George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.